Clinical Trial Update: Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adjuvant Benmelstobart for Stage IB, Grade 3 invasive lung adenocarcinoma (non-small cell lung cancer) is currently recruiting. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Benmelstobart

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING